Botulinum toxin injections for adults with overactive bladder syndrome

Botulinum toxin type A for the treatment of non‐neurogenic overactive bladder: does using onabotulinumtoxin A ( B otox ® ) or abobotulinumtoxin A ( D ysport ®

“…Symptomatic urinary retention requiring ISC is a well recognised side effect of botulinum toxin type A treatment for OAB . In our study, the ISC rate was nearly 100% in those with a PVR >250 mL.…”

Botulinum toxin type A for the treatment of non‐neurogenic overactive bladder: does using onabotulinumtoxin A ( B otox ® ) or abobotulinumtoxin A ( D ysport ®

“…Symptomatic urinary retention requiring ISC is a well recognised side effect of botulinum toxin type A treatment for OAB . In our study, the ISC rate was nearly 100% in those with a PVR >250 mL.…”

Treatment of Non-neurogenic Overactive Bladder with OnabotulinumtoxinA: Systematic Review and Meta-analysis of Prospective, Randomized, Placebo-controlled Clinical Trials

“…Such results are also in agreement with other systematic reviews and meta-analyses in respect to the subject. 18,19 There was significant reduction in the number of urinary urgency episodes in the group treated with toxin in comparison with the placebo group. However, none of the studies evaluated urgency intensity, probably because it is a subjective symptom, and it is very difficult to be characterized.…”

Medication adherence in the management of nocturia: challenges and solutions

“……”

Botulinum toxin type A for the treatment of non‐neurogenic overactive bladder: does using onabotulinumtoxin A ( B otox ® ) or abobotulinumtoxin A ( D ysport ®

“…Symptomatic urinary retention requiring ISC is a well recognised side effect of botulinum toxin type A treatment for OAB . In our study, the ISC rate was nearly 100% in those with a PVR >250 mL.…”

Treatment of Non-neurogenic Overactive Bladder with OnabotulinumtoxinA: Systematic Review and Meta-analysis of Prospective, Randomized, Placebo-controlled Clinical Trials

“…Such results are also in agreement with other systematic reviews and meta-analyses in respect to the subject. 18,19 There was significant reduction in the number of urinary urgency episodes in the group treated with toxin in comparison with the placebo group. However, none of the studies evaluated urgency intensity, probably because it is a subjective symptom, and it is very difficult to be characterized.…”

Medication adherence in the management of nocturia: challenges and solutions

“……”

Botulinum toxin type A for the treatment of non‐neurogenic overactive bladder: does using onabotulinumtoxin A ( B otox ® ) or abobotulinumtoxin A ( D ysport ®

“…Symptomatic urinary retention requiring ISC is a well recognised side effect of botulinum toxin type A treatment for OAB . In our study, the ISC rate was nearly 100% in those with a PVR >250 mL.…”

Treatment of Non-neurogenic Overactive Bladder with OnabotulinumtoxinA: Systematic Review and Meta-analysis of Prospective, Randomized, Placebo-controlled Clinical Trials

“…Such results are also in agreement with other systematic reviews and meta-analyses in respect to the subject. 18,19 There was significant reduction in the number of urinary urgency episodes in the group treated with toxin in comparison with the placebo group. However, none of the studies evaluated urgency intensity, probably because it is a subjective symptom, and it is very difficult to be characterized.…”

Medication adherence in the management of nocturia: challenges and solutions

“……”